Predictive model for variants associated with drug resistance and theranostic applications thereof
OwnerRaymond F. Schinazi, Dharmeshkumar Jethalal PATELinventors
Life of this patent
Estimating the term…
Abstract
Methods for predicting mutations in viruses, such as Coronaviruses, upon exposure to antiviral drugs, are disclosed. Mutated, non-naturally occurring viruses including those mutations, and methods of treatment with drugs that remain effective against the mutated viruses, are disclosed. These predictive methods can be useful in properly treating Covid patients with small molecule antiviral compounds that are effective against the particular SARS-COV-2 variant infecting the patient.
Claims12
A predictive model for determining what mutations a virus is likely to develop in response to exposure to a drug that binds to a viral enzyme, comprising:
- a) obtaining a crystal structure of the viral enzyme, or a portion thereof, complexed with an inhibitor of the enzyme, where the complex occurs in a binding pocket of the enzyme or portion thereof;
- b) creating an in silico model of the crystal structure of the viral enzyme complexed with the inhibitor, which model maps out the amino acid sequence of the enzyme, or portion thereof, c) making changes to the amino acids in the binding pocket, and measuring, in silico, changes in the Gibbs free energy between the viral enzyme, or portion thereof, and the inhibitor, to identify mutations that would tend to cause the inhibitor to no longer remain bound to the binding pocket,
- d) obtaining a crystal structure of one or more substrates to which the enzyme binds when exerting its enzymatic function,
- e) creating an in silico model of the crystal structure of the viral enzyme complexed with the one or more substrates, which model maps out the amino acid sequence of the enzyme, or portion thereof, and
- f) making changes to the amino acids in the binding pocket mirroring the changes identified in step c), and
- g) identifying those changes to the amino acids in the binding pocket that do not result in a likelihood that the enzyme will not remain bound to the binding pocket,
- wherein where a mutation would likely cause the inhibitor to no longer bind with high affinity to the enzyme, or portion thereof, but not significantly decrease the affinity of the enzyme to the one or more substrates, this correlates to a mutation that the virus would likely make upon exposure to the inhibitor.
Dependencies are inferred from the claim text.